Advertisement
Advertisement
LGVN
Longeveron Inc. Common Stock
0.70
USDSponsored
+0.03
+3.88%
Jul 31, 15:59 UTC -4
Closed
After-Market
0.70
0.00
-0.07%
LGVN Earnings Reports
Positive Surprise Ratio
LGVN beat 6 of 18 last estimates.
33%
Next Report
In 5 Days
Date of Next Report
Aug 07, 2026
Estimate for Q2 26 (Revenue/ EPS)
$340.68K
/-$0.17
Implied change from Q1 26 (Revenue/ EPS)
-14.40%
/-10.53%
Implied change from Q2 25 (Revenue/ EPS)
+7.81%
/-48.48%
Longeveron Inc. Common Stock earnings per share and revenue
On May 13, 2026, LGVN reported earnings of -0.19 USD per share (EPS) for Q1 26, missing the estimate of -0.16 USD, resulting in a -12.89% surprise. Revenue reached 398.00 thousand, compared to an expected 320.96 thousand, with a 24.00% difference. The market reacted with a -6.94% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.17 USD, with revenue projected to reach 340.68 thousand USD, implying an decrease of -10.53% EPS, and decrease of -14.40% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
FibroBiologics, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.66
Surprise
+10.13%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.21
Surprise
-23.70%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.00
Surprise
-90.05%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.13%
Anavex Life Sciences
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.06
Surprise
+15.97%
FAQ
What were Longeveron Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Longeveron Inc. Common Stock reported EPS of -$0.19, missing estimates by -12.89%, and revenue of $398.00K, 24% above expectations.
How did the market react to Longeveron Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -6.94%, changed from $0.76 before the earnings release to $0.70 the day after.
When is Longeveron Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 07, 2026.
What are the forecasts for Longeveron Inc. Common Stock's next earnings report?
Based on --
analysts, Longeveron Inc. Common Stock is expected to report EPS of -$0.17 and revenue of $340.68K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement